RadNet, Inc.
RDNT Mid CapHealthcare · Diagnostics & Research
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
RadNet, Inc. en bref
RadNet, Inc. (RDNT) is currently trading at 46,90 € with a market capitalization of 3,7 Md €. The 52-week range spans from 44,30 € to 74,91 €; the current price is 37.4% below the yearly high. Year-over-year revenue growth stands at +22.1%.
💰 Dividende
RadNet, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
8 analystes évaluent RadNet, Inc. (RDNT) au consensus : Achat Fort. L'objectif de cours moyen est de 78,32 €, soit un potentiel de +67.01% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 56,72 € à 87,27 €.
RadNet, Inc. : la thèse d'investissement en détail
RadNet, Inc. (RDNT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 22.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Strong Buy with an average price target implying roughly 67.01% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 13.8% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valorisation en contexte
With a PEG ratio of 0.96, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 67.01% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 22.1% sur un an
- Consensus des analystes : Strong Buy
- Free cash flow positif
- –Actuellement non rentable
- –Positions vendeuses élevées (13.8%)
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to market-like volatility, elevated short interest (13.8%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy RadNet, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
